{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000003","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.531268+00:00","generated_at":"2026-06-20T18:29:39.057331+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine and Voyager form $175M upfront gene therapy collaboration for GBA1 and rare CNS targets","bullets":["$175M upfront: ~$136M cash to Voyager plus $39M equity at $8.88/share (50% premium to 30-day VWAP).","Up to $1.5B in development milestones (GBA1 ≤$985M; each of three new CNS programs ≤$175M) plus commercial milestones & royalties.","Voyager can opt for 50/50 US co-dev/co-commercial on GBA1 after Phase 1 data; otherwise tiered royalties (low-double-digit to 20% US).","Three new rare CNS gene therapy programs leverage Voyager's TRACER capsids; Neurocrine funds all development costs.","Jude Onyia, Ph.D. (Neurocrine CSO), to join Voyager's board effective closing."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000003","json":"https://secwatch.observer/filing/0000914475-23-000003.json","markdown":"https://secwatch.observer/filing/0000914475-23-000003.md","text":"https://secwatch.observer/filing/0000914475-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/nbix-20230108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:29:39.057331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9158ac9dead4f84edd5165581822286255a69760","claim":"NEUROCRINE BIOSCIENCES INC entered into Collaboration and License Agreement with Voyager Therapeutics, Inc. valued at approximately $136.0 million (effective 2023-01-08).","evidence_excerpt":"On January 8, 2023 (the “Agreement Date”), Neurocrine Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Voyager Therapeutics, Inc. (“Voyager”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Voyager Therapeutics, Inc."},{"label":"Value","value":"approximately $136.0 million"},{"label":"Effective","value":"2023-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}